Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sage Therapeutics

6.91
-0.0100-0.14%
Post-market: 6.910.00000.00%16:20 EDT
Volume:1.08M
Turnover:7.40M
Market Cap:424.83M
PE:-1.05
High:7.02
Open:6.78
Low:6.70
Close:6.92
Loading ...

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

Zacks
·
21 Nov 2024

Sage Therapeutics price target lowered to $9 from $10 at TD Cowen

TIPRANKS
·
21 Nov 2024

Scotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)

TIPRANKS
·
21 Nov 2024

Oppenheimer Sticks to Its Hold Rating for SAGE Therapeutics (SAGE)

TIPRANKS
·
21 Nov 2024

Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

TIPRANKS
·
21 Nov 2024

Sage Therapeutics price target lowered to $4 from $7 at BofA

TIPRANKS
·
21 Nov 2024

RBC Upgrades SAGE Therapeutics to Sector Perform From Underperform, Keeps Speculative Risk, $4 Price Target

MT Newswires Live
·
21 Nov 2024

SAGE Therapeutics: Analyst Reiterates Sell Rating Amid Pipeline Setbacks and Prescriber Challenges

TIPRANKS
·
21 Nov 2024

U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target

Reuters
·
21 Nov 2024

Sage Therapeutics Inc : RBC Raises to Sector Perform From Underperform

THOMSON REUTERS
·
21 Nov 2024

Sage Therapeutics Inc : TD Cowen Cuts Target Price to $9 From $10

THOMSON REUTERS
·
21 Nov 2024

SAGE Therapeutics: Hold Rating Amid Dalzanemdor’s Phase 2 Failure and Valuation Adjustments

TIPRANKS
·
21 Nov 2024

RBC upgrades Sage to Sector Perform with negative thesis played out

TIPRANKS
·
21 Nov 2024

Sage Therapeutics upgraded to Sector Perform from Underperform at RBC Capital

TIPRANKS
·
21 Nov 2024

Sage Therapeutics Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Nov 2024

Sage Therapeutics reported another clinical setback, says H.C. Wainwright

TIPRANKS
·
21 Nov 2024

SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Strategic Shifts

TIPRANKS
·
21 Nov 2024

Sage Therapeutics Shares Reverse Course; Last up 4.3%

THOMSON REUTERS
·
20 Nov 2024

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

Benzinga
·
20 Nov 2024

Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating

MT Newswires Live
·
20 Nov 2024